NR3C1 and metabolic syndrome: GR involvement in the pathophysiology of the metabolic syndrome has been studied by using GR antagonists (RU486) that improve insulin resistance and glucose tolerance, but also via constitutive or inducible mouse models of adipose-specific GR KO [72,83,84,85,86,87].